AllianceBernstein
BDTX icon

AllianceBernstein’s Black Diamond Therapeutics BDTX Stock Holding History

AllianceBernstein’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,640
Closed -$33.5K – 3242
2025
Q1 		$33.5K Hold
21,640
– – ﹤0.01% 3161
2024
Q4 		$46.3K Hold
21,640
– – ﹤0.01% 3189
2024
Q3 		$94.1K Buy
21,640
+4,300
+25% +$23.4K ﹤0.01% 3139
2024
Q2 		$80.8K Buy
+17,340
New +$93.1K ﹤0.01% 3142
2022
Q2 		– Sell
-34,600
Closed -$96K – 3274
2022
Q1 		$96K Buy
34,600
+100
+0.3% +$365 ﹤0.01% 3117
2021
Q4 		$184K Hold
34,500
– – ﹤0.01% 3093
2021
Q3 		$292K Hold
34,500
– – ﹤0.01% 2959
2021
Q2 		$421K Buy
34,500
+19,600
+132% +$387K ﹤0.01% 2885
2021
Q1 		$361K Hold
14,900
– – ﹤0.01% 2826
2020
Q4 		$478K Buy
14,900
+600
+4% +$19.7K ﹤0.01% 2617
2020
Q3 		$432K Sell
14,300
-800
-5% -$24.3K ﹤0.01% 2597
2020
Q2 		$637K Buy
15,100
+6,200
+70% +$228K ﹤0.01% 2454
2020
Q1 		$222K Buy
+8,900
New +$271K ﹤0.01% 2756

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AllianceBernstein's BDTX Position: Q2 2025 in Review

AllianceBernstein sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 21,640 shares — an estimated $33.5K sold.

AllianceBernstein first reported a position in BDTX in Q1 2020 and held it in 13 quarters. The position peaked at $637K in Q2 2020. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • AllianceBernstein reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 21,640 Black Diamond Therapeutics shares in Q2 2025, an estimated $33.5K.
  • AllianceBernstein first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 13 quarters.
  • AllianceBernstein's Black Diamond Therapeutics position peaked at $637K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.